Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed exchanges that its subsidiary Optival Health Solutions received two suspension orders for drug licenses of stores in Karnataka from the Assistant Director, Drugs Control Administration, Bangalore. The first store at Ujjini Road, Kotturu received a 2-day suspension, while the second store at Ramakrishna Road, Hoskote received a 1-day suspension. The orders were received on August 25, 2025, and were issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The combined potential revenue loss from both suspensions is approximately Rs 1.06 lacs, which is negligible relative to company operations.
The financial impact is immaterial at roughly Rs 1.06 lacs in potential revenue loss, so this is unlikely to affect the stock price. It reflects routine regulatory compliance for retail pharmacy operations rather than any systemic issue.